
|Podcasts|July 26, 2021
Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
Author(s)Elizabeth Yeu, MD, Alex Delaney-Gesing
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
4
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
5























